TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 12/30/25

2025-12-30 09:02:32 ET More related stories Meta: The AI Revenue Leader Nobody Is Talking About Meta: The Company Benefiting From AI Right Now Novo Nordisk: The Real Comeback Starts Now With The Wegovy Pill Takeda, XOMA ink new royalty agreement; amend existi...

2025-12-30 08:14:57 ET More on Takeda Pharmaceutical, XOMA Takeda: Lack Of Realistic Upside In Japanese Pharma Takeda Pharmaceutical Company Limited (TAK) Q2 FY2025 Earnings Call Transcript Takeda Pharmaceutical Company Limited FY2025 Q2 - Results - Earnings Call Pre...

2025-12-18 13:03:50 ET More on Takeda Pharmaceutical Takeda: Lack Of Realistic Upside In Japanese Pharma Takeda Pharmaceutical Company Limited (TAK) Q2 FY2025 Earnings Call Transcript Takeda Pharmaceutical Company Limited FY2025 Q2 - Results - Earnings Call Presentat...

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 perce...

British Columbia reimburses FRUZAQLATM (fruquintinib capsules) for the treatment of metastatic colorectal cancer (mCRC) Canada NewsWire TORONTO , Dec. 16, 2025 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLA TM (fruquintinib capsules) will now be r...

2025-12-15 14:50:59 ET The last time I spoke about AC Immune ( ACIU ), it was with respect to a Seeking Alpha article entitled " AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward ". With respect to this article, I noted that the company was in the process of d...

2025-12-11 18:29:52 ET I've been reviewing adjacent and peer pharma companies to Takeda (TAK) for some time, without looking at Takeda. So over the past few weeks, I looked more into Takeda and "did the work" to more closely analyze and cover it.... Read the full article on Seekin...

2025-12-08 12:02:09 ET I've been a frequent analyst for covering Grifols, S.A. ( GRFS ) as a business here on Seeking Alpha. The world's largest blood plasma business, with other adjacent/related businesses, is going through a renaissance, rising like a phoenix from the ashes of wha...

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety Signals These Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficac...

2025-11-27 07:20:44 ET Introduction As the year comes to an end, we must be thankful for the therapies that are in late clinical stages. Most importantly, patients are set to benefit immensely. But nearly every trial candidate has implications beyond just patients. The approval of a...